Apple Taiwanese Supplier Pegatron Eyes India As Next Growth Frontier For 2nd Factory – $AAPL $DIA $SPY $INVO

Published Apr 04, 2023
Apple
INVO Bioscience
Technology & Beyond

By John F. Heerdink, Jr.

Reportedly, Pegatron Corp, a Taiwanese firm that provides products to Apple Inc. (AAPL), is in talks to construct a second production plant in India. The proposed plant is expected to be located in close proximity to Chennai, a city in the southern state of Tamil Nadu, just six months following the opening of the company’s initial facility in the country, which cost $150 million. India has been recognized as a promising market for Apple, with smartphone exports valued at around $9 billion from April 2022 to February 2023, with iPhones accounting for more than 50% of these exports, as per the India Cellular and Electronics Association.

Pegatron is responsible for roughly 10% of Apple’s iPhone production in India each year, according to research firm Counterpoint. Due to growing trade tensions between China and the United States, Apple and its key suppliers have been relocating production to other regions, and Pegatron has been expanding its operations in Southeast Asia and North America in recent years. Talks for the new Pegatron facility are ongoing, and the plant will be situated inside Mahindra World City near Chennai, in the same vicinity as the company’s first plant which was inaugurated in September 2022.

Dow 30 component Apple (AAPL) revolutionized personal technology with the introduction of the Macintosh in 1984. Today Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch, and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS, and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay, and iCloud. Apple’s more than 100,000 employees are dedicated to making the best products on earth, and to “leaving the world better than they found it. To learn more about Apple (AAPL) and track its ongoing progress at Vista Partners Apple (AAPL), Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

DID YOU KNOW?…

On Monday, March 20, INVO Bioscience (NASDAQ: INVO) announced that it has signed binding agreements to acquire a materially transformative acquisition of the Wisconsin Fertility Institute. The Madison-based fertility center primarily offers conventional IVF procedures and generated approximately $5.5 million in revenue and net income of approximately $1.9 million for the trailing 12-month period ended September 30, 2022.

Wisconsin Fertility Institute is led by internationally renowned and well-respected fertility expert, Dr. Elizabeth Pritts, who will continue to serve as the clinic’s lead physician for a minimum period of three years from the closing of the acquisition. Dual-certified in General Obstetrics and Gynecology, as well as Reproductive Endocrinology and Infertility, Dr. Pritts completed a surgical fellowship in Advanced Gynecologic Laparoscopy and Hysteroscopy. She is also a national leader in the use of robotic surgery for gynecologic disorders. Dr. Pritts served as an assistant professor in reproductive endocrinology and infertility at the University of Wisconsin Medical School, as a clinical fellow at the University of California at San Francisco, and as an instructor at Yale University School of Medicine. She has authored more than 70 articles for scientific publications and has lectured throughout the world on reproduction and fertility.

Dr. Elizabeth Pritts, M.D., Wisconsin Fertility Institute’s Co-founder

“I’m excited to be teaming up with INVO as a unique and attractive partner to help advance us to the next phase of our practice. INVO’s commercial strategy and patient focus, along with its public-company platform and the INVOcell technology itself, offers an exciting pathway to build value and increase access to an efficient, effective, affordable, and connected experience in reproductive treatment. Our team looks forward to being an integral part of INVO’s long-term growth and success.” Dr. Elizabeth Pritts, Wisconsin Fertility Institute’s co-founder.

Wisconsin Fertility Institute joins INVO’s expanding list of fertility clinics, including operating clinics in Atlanta (Bloom Fertility), Birmingham (Innovative Fertility Specialists) and Monterrey, Mexico (Positib Fertility), as well as future clinics under development, such as the wholly owned INVO Center in Tampa, Florida that is currently under construction. INVO’s revolutionary medical device, the INVOcell, allows fertilization and early embryo development to occur in vivo with the woman’s body and is also available at a growing list of non-affiliated fertility centers in the United States and around the world.